A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/1997
10/28/1997	US5681860 Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol
10/28/1997	US5681847 Administering anticarcinogenic lactone compounds
10/28/1997	US5681841 Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
10/28/1997	US5681835 Useful for treating osteoporosis
10/28/1997	US5681822 Shelf stable solutions of cladribine in benzyl alcohol
10/28/1997	US5681817 Treatment of ovarian estrogen dependent conditions
10/28/1997	US5681747 Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
10/28/1997	US5681589 Anticancer agents
10/23/1997	WO1997039127A1 Hybrid interferon compositions and methods of use
10/23/1997	WO1997039126A1 Novel rantes homolog from prostate
10/23/1997	WO1997039123A2 Secreted proteins
10/23/1997	WO1997039102A2 Secreted proteins
10/23/1997	WO1997039025A1 A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp.
10/23/1997	WO1997039024A1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
10/23/1997	WO1997039023A1 Cysteine-containing or methioine-containing peptides with immunomodulatory effects
10/23/1997	WO1997038999A1 Acridone-derived compounds useful as antineoplastic and antiretroviral agents
10/23/1997	WO1997038986A1 Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors
10/23/1997	WO1997038983A1 Irreversible inhibitors of tyrosine kinases
10/23/1997	WO1997038731A1 Immunoliposomes that optimize internalization into target cells
10/23/1997	WO1997038724A1 New indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses
10/23/1997	WO1997038703A1 Chimeric isoprenoid synthases and uses thereof
10/23/1997	WO1997038697A1 Sensitization of cells to radiation and chemotherapy
10/23/1997	WO1997038689A2 Enteric-coated pharmaceutical compositions of mycophenolate
10/23/1997	WO1997038665A2 Inhibitors of farnesyl-protein transferase
10/23/1997	WO1997038664A2 A method of treating cancer
10/23/1997	WO1997031657A3 Use of labelled cck-b receptor ligands for the detection and localization of malignant human tumors
10/23/1997	WO1997031019A3 Antipathogenic peptides and compositions comprising them
10/23/1997	WO1997026918A3 Ligand directed enzyme prodrug therapy
10/23/1997	WO1997025068A3 Mesothelin antigen and methods and kits for targeting it
10/23/1997	DE19617837A1 Anticancer vaccine containing human dendritic cells
10/23/1997	DE19615812A1 Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation Pharmaceutical preparation for oral administration containing diphosphonic acids
10/23/1997	DE19615803A1 CELO-Virus CELO virus
10/23/1997	DE19615710A1 Verfahren zur Gewinnung und Anwendung eines biologisch aktiven Eiweisstoffes - Kollagenfragment HF-COLL-18/514cf - in partiell aufgereinigter und synthetischer Form aus Körperflüssigkeiten zur Beeinflussung des Zellwachstums und der Diagnose von Kollagenerkrankungen sowie der Osteoporose Methods for obtaining and application of a biologically active Eiweisstoffes - collagen fragment HF-COLL-18 / 514cf - in partially purified form from body fluids and synthetic for influencing the cell growth and the diagnosis of collagen diseases and osteoporosis
10/23/1997	CA2252099A1 A cyclic hepta-peptide derivative from colonial ascidians, lissoclinum sp.
10/23/1997	CA2252082A1 Hybrid interferon compositions and methods of use
10/23/1997	CA2251955A1 A method of treating cancer
10/23/1997	CA2251716A1 Sensitization of cells to radiation and chemotherapy
10/23/1997	CA2251115A1 Novel rantes homolog from prostate
10/23/1997	CA2250707A1 Cysteine-containing or methionine-containing peptides with immunomodulatory effects
10/23/1997	CA2249601A1 Inhibitors of farnesyl-protein transferase
10/23/1997	CA2219151A1 Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
10/22/1997	EP0801951A2 Novel uses of Il-4 and/or Il-10, and antibodies against the same
10/22/1997	EP0801656A1 Induction of cytotoxic t-lymphocyte responses
10/22/1997	EP0801649A2 Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
10/22/1997	EP0801574A1 Modulation of integrin-mediated signal transduction
10/22/1997	EP0801571A1 Soluble 2-chloro-2'-deoxyadenosine formulations
10/22/1997	EP0684948B1 Meso-tetraphenyl porphyrin complex compounds, process for preparing the same and pharmaceuticals containing the same
10/22/1997	EP0679093B1 Methods of delivering agents to target cells
10/22/1997	CN1162461A Anti-cancer medicine with extracts from goldenrain and the preparation thereof
10/21/1997	US5679782 Inhibit receptor binding activity of urokinase-type plasminogen activator
10/21/1997	US5679700 Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
10/21/1997	US5679683 Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
10/21/1997	US5679647 Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
10/21/1997	US5679644 Methods of treating diseases using triterpenoid acid derivatives
10/21/1997	US5679641 Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
10/21/1997	US5679339 Method of using IL-11 for treating spondyloarthropies
10/21/1997	CA1339502C Anti-cancer activity potentiator
10/16/1997	WO1997038104A1 Il-6 mutein
10/16/1997	WO1997038103A1 Il-6 mutein
10/16/1997	WO1997038102A1 Multivalent and multispecific antigen-binding protein
10/16/1997	WO1997038100A1 Human cachexia associated protein
10/16/1997	WO1997038085A2 Genes amplified in cancer cells
10/16/1997	WO1997038084A2 Polynucleotides derived from a pbmc cdna library encoding secreted proteins
10/16/1997	WO1997038013A1 Modulation of mammalian telomerase by peptide nucleic acids
10/16/1997	WO1997038011A1 Non-dendritic backbone peptide carrier
10/16/1997	WO1997038009A1 Cyclic adhesion inhibitors
10/16/1997	WO1997038008A1 6-substituted amino-4-oxa-1-azabicyclo[3,2,0] heptan-7-one deriv atives as cysteine protease inhibitors
10/16/1997	WO1997038007A1 Peptidyl compounds having mmp and tnf- liberation inhibitory activity
10/16/1997	WO1997037974A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/16/1997	WO1997037973A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/16/1997	WO1997037972A1 Novel vitamin d analogues
10/16/1997	WO1997037684A1 Method for gene transfer to the central nervous system
10/16/1997	WO1997037678A1 Drug for the treatment of tumours
10/16/1997	WO1997037658A1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
10/16/1997	WO1997037655A1 αvβ3 ANTAGONISTS
10/16/1997	WO1997024138A3 Medical use of proteases
10/16/1997	WO1997022619A3 INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
10/16/1997	CA2578825A1 5-androstene 3.beta., 17.alpha. diol as an inhibitor of tumor growth
10/16/1997	CA2252086A1 6-substituted amino-4-oxa-1-azabicyclo¬3,2,0\|heptan-7-one derivatives as cysteine protease inhibitors
10/16/1997	CA2251464A1 Non-dendritic backbone peptide carrier
10/16/1997	CA2251017A1 .alpha.v.beta.3 antagonists
10/16/1997	CA2250898A1 Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
10/16/1997	CA2250868A1 Human cachexia associated protein
10/16/1997	CA2250860A1 Polynucleotides encoding secreted proteins
10/16/1997	CA2250839A1 Drug for the treatment of tumours
10/16/1997	CA2248949A1 Novel furan diarylmethylidene derivatives, method for their preparation and therapeutical uses thereof
10/16/1997	CA2248082A1 Peptidyl compounds having mmp and tnf- liberation inhibitory activity
10/16/1997	CA2248070A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/16/1997	CA2247964A1 Peptidyl compounds having mmp and tnf inhibitory activity
10/15/1997	EP0800829A1 Antitumor agent potentiator comprising il-6 antagonist
10/15/1997	EP0800826A2 Apoptosis-controlling agent
10/15/1997	EP0800581A1 POLYMERASE $g(d) MUTATIONS IN COLORECTAL TUMORS WITH REPLICATION ERRORS
10/15/1997	EP0800578A2 Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen
10/15/1997	EP0800534A2 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
10/15/1997	EP0800532A1 Improved cyclic crf agonists
10/15/1997	EP0800517A1 Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
10/15/1997	EP0800510A1 Hydroxamic acid-containing inhibitors of matrix metalloproteases
10/15/1997	EP0800504A1 Tricyclic retinoids, methods for their production and use
10/15/1997	EP0800503A1 Novel trienoic retinoid compounds and methods
10/15/1997	EP0800399A1 Combined therapeutical treatment of hyperproliferative diseases

1 ... 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 ... 2211